

Global Severe Eosinophilic Asthma Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GD83D051A02EEN.html>

Date: June 2026

Pages: 133

Price: US\$ 3,480.00 (Single User License)

ID: GD83D051A02EEN

Abstracts

According to our (Global Info Research) latest study, the global Severe Eosinophilic Asthma Treatment market size was valued at US\$ 8664 million in 2025 and is forecast to a readjusted size of US\$ 17519 million by 2032 with a CAGR of 10.5% during review period.

The gross profit margin of major companies in the industry is between 58% ? 78%.

Severe Eosinophilic Asthma Treatment refers to therapeutic regimens used for patients with severe asthma characterized by elevated eosinophil-driven inflammation. The category includes biologics, targeted monoclonal antibodies, and advanced maintenance therapies aimed at reducing exacerbations, improving lung function, and lowering corticosteroid dependence. It has become an important segment within specialty respiratory care and precision immunology treatment.

The industrial chain of Severe Eosinophilic Asthma Treatment includes upstream biologic raw materials, cell culture media, active pharmaceutical ingredients, vials, syringes, and cold-chain materials. Midstream covers drug development, biomanufacturing, filling, packaging, and regulatory control. Downstream applications mainly include hospitals, specialty clinics, respiratory care centers, pharmacies, and long-term chronic disease management programs.

The market for severe eosinophilic asthma treatments is expanding due to rising prevalence of respiratory diseases and unmet medical needs. Biologics targeting eosinophilic inflammation have become mainstream for uncontrolled severe asthma. Increasing diagnosis rates, improved access to specialty drugs, and favorable

reimbursement policies support growth. Companies focus on innovative targeted therapies and long-term safety to strengthen clinical competitiveness.

This report is a detailed and comprehensive analysis for global Severe Eosinophilic Asthma Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Severe Eosinophilic Asthma Treatment market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Severe Eosinophilic Asthma Treatment market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Severe Eosinophilic Asthma Treatment market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Severe Eosinophilic Asthma Treatment market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Severe Eosinophilic Asthma Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Severe Eosinophilic Asthma Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies

covered as a part of this study include AstraZeneca, GSK (GlaxoSmithKline), Sanofi, Regeneron Pharmaceuticals, Novartis, Roche (Genentech), Teva Pharmaceutical, Amgen, TEPPON (Kyowa Kirin), Jiangsu Hengrui Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Severe Eosinophilic Asthma Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Intravenous Infusion

Subcutaneous Injection

Market segment by Administration Route

Inhalation Therapy

Subcutaneous Injection Therapy

Intravenous Infusion Therapy

Market segment by Treatment Stage

Induction Remission Therapy

Maintenance Control Therapy

Exacerbation Rescue Therapy

Market segment by Application

Adult Severe Eosinophilic Asthma

Adolescent Severe Eosinophilic Asthma

Elderly Comorbid Asthma

Market segment by players, this report covers

AstraZeneca

GSK (GlaxoSmithKline)

Sanofi

Regeneron Pharmaceuticals

Novartis

Roche (Genentech)

Teva Pharmaceutical

Amgen

TEPPON (Kyowa Kirin)

Jiangsu Hengrui Pharmaceuticals

CSPC Pharmaceutical Group

3SBio (Sunshine Guojian)

Akeso

InnoCare Pharma

Innovent Biologics

Mabwell Bioscience

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Severe Eosinophilic Asthma Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Severe Eosinophilic Asthma Treatment, with revenue, gross margin, and global market share of Severe Eosinophilic Asthma Treatment from 2021 to 2026.

Chapter 3, the Severe Eosinophilic Asthma Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Severe Eosinophilic Asthma Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Severe Eosinophilic Asthma Treatment.

Chapter 13, to describe Severe Eosinophilic Asthma Treatment research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Severe Eosinophilic Asthma Treatment by Type

1.3.1 Overview: Global Severe Eosinophilic Asthma Treatment Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type in 2025

1.3.3 Intravenous Infusion

1.3.4 Subcutaneous Injection

1.4 Classification of Severe Eosinophilic Asthma Treatment by Administration Route

1.4.1 Overview: Global Severe Eosinophilic Asthma Treatment Market Size by Administration Route: 2021 Versus 2025 Versus 2032

1.4.2 Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Administration Route in 2025

1.4.3 Inhalation Therapy

1.4.4 Subcutaneous Injection Therapy

1.4.5 Intravenous Infusion Therapy

1.5 Classification of Severe Eosinophilic Asthma Treatment by Treatment Stage

1.5.1 Overview: Global Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage: 2021 Versus 2025 Versus 2032

1.5.2 Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Treatment Stage in 2025

1.5.3 Induction Remission Therapy

1.5.4 Maintenance Control Therapy

1.5.5 Exacerbation Rescue Therapy

1.6 Global Severe Eosinophilic Asthma Treatment Market by Application

1.6.1 Overview: Global Severe Eosinophilic Asthma Treatment Market Size by Application: 2021 Versus 2025 Versus 2032

1.6.2 Adult Severe Eosinophilic Asthma

1.6.3 Adolescent Severe Eosinophilic Asthma

1.6.4 Elderly Comorbid Asthma

1.7 Global Severe Eosinophilic Asthma Treatment Market Size & Forecast

1.8 Global Severe Eosinophilic Asthma Treatment Market Size and Forecast by Region

1.8.1 Global Severe Eosinophilic Asthma Treatment Market Size by Region: 2021 VS 2025 VS 2032

1.8.2 Global Severe Eosinophilic Asthma Treatment Market Size by Region,
(2021-2032)

1.8.3 North America Severe Eosinophilic Asthma Treatment Market Size and Prospect
(2021-2032)

1.8.4 Europe Severe Eosinophilic Asthma Treatment Market Size and Prospect
(2021-2032)

1.8.5 Asia-Pacific Severe Eosinophilic Asthma Treatment Market Size and Prospect
(2021-2032)

1.8.6 South America Severe Eosinophilic Asthma Treatment Market Size and Prospect
(2021-2032)

1.8.7 Middle East & Africa Severe Eosinophilic Asthma Treatment Market Size and
Prospect (2021-2032)

2 COMPANY PROFILES

2.1 AstraZeneca

2.1.1 AstraZeneca Details

2.1.2 AstraZeneca Major Business

2.1.3 AstraZeneca Severe Eosinophilic Asthma Treatment Product and Solutions

2.1.4 AstraZeneca Severe Eosinophilic Asthma Treatment Revenue, Gross Margin
and Market Share (2021-2026)

2.1.5 AstraZeneca Recent Developments and Future Plans

2.2 GSK (GlaxoSmithKline)

2.2.1 GSK (GlaxoSmithKline) Details

2.2.2 GSK (GlaxoSmithKline) Major Business

2.2.3 GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Product and
Solutions

2.2.4 GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Revenue, Gross
Margin and Market Share (2021-2026)

2.2.5 GSK (GlaxoSmithKline) Recent Developments and Future Plans

2.3 Sanofi

2.3.1 Sanofi Details

2.3.2 Sanofi Major Business

2.3.3 Sanofi Severe Eosinophilic Asthma Treatment Product and Solutions

2.3.4 Sanofi Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and
Market Share (2021-2026)

2.3.5 Sanofi Recent Developments and Future Plans

2.4 Regeneron Pharmaceuticals

2.4.1 Regeneron Pharmaceuticals Details

- 2.4.2 Regeneron Pharmaceuticals Major Business
- 2.4.3 Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Solutions
- 2.4.4 Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
- 2.5 Novartis
 - 2.5.1 Novartis Details
 - 2.5.2 Novartis Major Business
 - 2.5.3 Novartis Severe Eosinophilic Asthma Treatment Product and Solutions
 - 2.5.4 Novartis Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 2.5.5 Novartis Recent Developments and Future Plans
- 2.6 Roche (Genentech)
 - 2.6.1 Roche (Genentech) Details
 - 2.6.2 Roche (Genentech) Major Business
 - 2.6.3 Roche (Genentech) Severe Eosinophilic Asthma Treatment Product and Solutions
 - 2.6.4 Roche (Genentech) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 2.6.5 Roche (Genentech) Recent Developments and Future Plans
- 2.7 Teva Pharmaceutical
 - 2.7.1 Teva Pharmaceutical Details
 - 2.7.2 Teva Pharmaceutical Major Business
 - 2.7.3 Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Product and Solutions
 - 2.7.4 Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 2.7.5 Teva Pharmaceutical Recent Developments and Future Plans
- 2.8 Amgen
 - 2.8.1 Amgen Details
 - 2.8.2 Amgen Major Business
 - 2.8.3 Amgen Severe Eosinophilic Asthma Treatment Product and Solutions
 - 2.8.4 Amgen Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 2.8.5 Amgen Recent Developments and Future Plans
- 2.9 TEPPON (Kyowa Kirin)
 - 2.9.1 TEPPON (Kyowa Kirin) Details
 - 2.9.2 TEPPON (Kyowa Kirin) Major Business

2.9.3 TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Product and Solutions

2.9.4 TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 TEPPON (Kyowa Kirin) Recent Developments and Future Plans

2.10 Jiangsu Hengrui Pharmaceuticals

2.10.1 Jiangsu Hengrui Pharmaceuticals Details

2.10.2 Jiangsu Hengrui Pharmaceuticals Major Business

2.10.3 Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Solutions

2.10.4 Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments and Future Plans

2.11 CSPC Pharmaceutical Group

2.11.1 CSPC Pharmaceutical Group Details

2.11.2 CSPC Pharmaceutical Group Major Business

2.11.3 CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Product and Solutions

2.11.4 CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 CSPC Pharmaceutical Group Recent Developments and Future Plans

2.12 3SBio (Sunshine Guojian)

2.12.1 3SBio (Sunshine Guojian) Details

2.12.2 3SBio (Sunshine Guojian) Major Business

2.12.3 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Product and Solutions

2.12.4 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.12.5 3SBio (Sunshine Guojian) Recent Developments and Future Plans

2.13 Akeso

2.13.1 Akeso Details

2.13.2 Akeso Major Business

2.13.3 Akeso Severe Eosinophilic Asthma Treatment Product and Solutions

2.13.4 Akeso Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.13.5 Akeso Recent Developments and Future Plans

2.14 InnoCare Pharma

2.14.1 InnoCare Pharma Details

2.14.2 InnoCare Pharma Major Business

2.14.3 InnoCare Pharma Severe Eosinophilic Asthma Treatment Product and Solutions

2.14.4 InnoCare Pharma Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.14.5 InnoCare Pharma Recent Developments and Future Plans

2.15 Innovent Biologics

2.15.1 Innovent Biologics Details

2.15.2 Innovent Biologics Major Business

2.15.3 Innovent Biologics Severe Eosinophilic Asthma Treatment Product and Solutions

2.15.4 Innovent Biologics Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.15.5 Innovent Biologics Recent Developments and Future Plans

2.16 Mabwell Bioscience

2.16.1 Mabwell Bioscience Details

2.16.2 Mabwell Bioscience Major Business

2.16.3 Mabwell Bioscience Severe Eosinophilic Asthma Treatment Product and Solutions

2.16.4 Mabwell Bioscience Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

2.16.5 Mabwell Bioscience Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Severe Eosinophilic Asthma Treatment Revenue and Share by Players (2021-2026)

3.2 Market Share Analysis (2025)

3.2.1 Market Share of Severe Eosinophilic Asthma Treatment by Company Revenue

3.2.2 Top 3 Severe Eosinophilic Asthma Treatment Players Market Share in 2025

3.2.3 Top 6 Severe Eosinophilic Asthma Treatment Players Market Share in 2025

3.3 Severe Eosinophilic Asthma Treatment Market: Overall Company Footprint Analysis

3.3.1 Severe Eosinophilic Asthma Treatment Market: Region Footprint

3.3.2 Severe Eosinophilic Asthma Treatment Market: Company Product Type Footprint

3.3.3 Severe Eosinophilic Asthma Treatment Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Severe Eosinophilic Asthma Treatment Consumption Value and Market Share by Type (2021-2026)

4.2 Global Severe Eosinophilic Asthma Treatment Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2026)

5.2 Global Severe Eosinophilic Asthma Treatment Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2032)

6.2 North America Severe Eosinophilic Asthma Treatment Market Size by Application (2021-2032)

6.3 North America Severe Eosinophilic Asthma Treatment Market Size by Country

6.3.1 North America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2032)

6.3.2 United States Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

6.3.3 Canada Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

6.3.4 Mexico Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2032)

7.2 Europe Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2032)

7.3 Europe Severe Eosinophilic Asthma Treatment Market Size by Country

7.3.1 Europe Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2032)

7.3.2 Germany Severe Eosinophilic Asthma Treatment Market Size and Forecast

(2021-2032)

7.3.3 France Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

7.3.4 United Kingdom Severe Eosinophilic Asthma Treatment Market Size and
Forecast (2021-2032)

7.3.5 Russia Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

7.3.6 Italy Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Type
(2021-2032)

8.2 Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by
Application (2021-2032)

8.3 Asia-Pacific Severe Eosinophilic Asthma Treatment Market Size by Region

8.3.1 Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by
Region (2021-2032)

8.3.2 China Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

8.3.3 Japan Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

8.3.4 South Korea Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

8.3.5 India Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

8.3.6 Southeast Asia Severe Eosinophilic Asthma Treatment Market Size and
Forecast (2021-2032)

8.3.7 Australia Severe Eosinophilic Asthma Treatment Market Size and Forecast
(2021-2032)

9 SOUTH AMERICA

9.1 South America Severe Eosinophilic Asthma Treatment Consumption Value by Type
(2021-2032)

9.2 South America Severe Eosinophilic Asthma Treatment Consumption Value by
Application (2021-2032)

9.3 South America Severe Eosinophilic Asthma Treatment Market Size by Country

9.3.1 South America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2032)

9.3.2 Brazil Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

9.3.3 Argentina Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2032)

10.2 Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2032)

10.3 Middle East & Africa Severe Eosinophilic Asthma Treatment Market Size by Country

10.3.1 Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2032)

10.3.2 Turkey Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

10.3.4 UAE Severe Eosinophilic Asthma Treatment Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Severe Eosinophilic Asthma Treatment Market Drivers

11.2 Severe Eosinophilic Asthma Treatment Market Restraints

11.3 Severe Eosinophilic Asthma Treatment Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Severe Eosinophilic Asthma Treatment Industry Chain

- 12.2 Severe Eosinophilic Asthma Treatment Upstream Analysis
- 12.3 Severe Eosinophilic Asthma Treatment Midstream Analysis
- 12.4 Severe Eosinophilic Asthma Treatment Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Severe Eosinophilic Asthma Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Severe Eosinophilic Asthma Treatment Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032

Table 3. Global Severe Eosinophilic Asthma Treatment Consumption Value by Treatment Stage, (USD Million), 2021 & 2025 & 2032

Table 4. Global Severe Eosinophilic Asthma Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Global Severe Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026) & (USD Million)

Table 6. Global Severe Eosinophilic Asthma Treatment Consumption Value by Region (2027-2032) & (USD Million)

Table 7. AstraZeneca Company Information, Head Office, and Major Competitors

Table 8. AstraZeneca Major Business

Table 9. AstraZeneca Severe Eosinophilic Asthma Treatment Product and Solutions

Table 10. AstraZeneca Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 11. AstraZeneca Recent Developments and Future Plans

Table 12. GSK (GlaxoSmithKline) Company Information, Head Office, and Major Competitors

Table 13. GSK (GlaxoSmithKline) Major Business

Table 14. GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Product and Solutions

Table 15. GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 16. GSK (GlaxoSmithKline) Recent Developments and Future Plans

Table 17. Sanofi Company Information, Head Office, and Major Competitors

Table 18. Sanofi Major Business

Table 19. Sanofi Severe Eosinophilic Asthma Treatment Product and Solutions

Table 20. Sanofi Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 21. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 22. Regeneron Pharmaceuticals Major Business

Table 23. Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Product

and Solutions

Table 24. Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 25. Regeneron Pharmaceuticals Recent Developments and Future Plans

Table 26. Novartis Company Information, Head Office, and Major Competitors

Table 27. Novartis Major Business

Table 28. Novartis Severe Eosinophilic Asthma Treatment Product and Solutions

Table 29. Novartis Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 30. Novartis Recent Developments and Future Plans

Table 31. Roche (Genentech) Company Information, Head Office, and Major Competitors

Table 32. Roche (Genentech) Major Business

Table 33. Roche (Genentech) Severe Eosinophilic Asthma Treatment Product and Solutions

Table 34. Roche (Genentech) Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 35. Roche (Genentech) Recent Developments and Future Plans

Table 36. Teva Pharmaceutical Company Information, Head Office, and Major Competitors

Table 37. Teva Pharmaceutical Major Business

Table 38. Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Product and Solutions

Table 39. Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 40. Teva Pharmaceutical Recent Developments and Future Plans

Table 41. Amgen Company Information, Head Office, and Major Competitors

Table 42. Amgen Major Business

Table 43. Amgen Severe Eosinophilic Asthma Treatment Product and Solutions

Table 44. Amgen Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 45. Amgen Recent Developments and Future Plans

Table 46. TEPPON (Kyowa Kirin) Company Information, Head Office, and Major Competitors

Table 47. TEPPON (Kyowa Kirin) Major Business

Table 48. TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Product and Solutions

Table 49. TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 50. TEPPON (Kyowa Kirin) Recent Developments and Future Plans
Table 51. Jiangsu Hengrui Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 52. Jiangsu Hengrui Pharmaceuticals Major Business
Table 53. Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Solutions
Table 54. Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Jiangsu Hengrui Pharmaceuticals Recent Developments and Future Plans
Table 56. CSPC Pharmaceutical Group Company Information, Head Office, and Major Competitors
Table 57. CSPC Pharmaceutical Group Major Business
Table 58. CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Product and Solutions
Table 59. CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. CSPC Pharmaceutical Group Recent Developments and Future Plans
Table 61. 3SBio (Sunshine Guojian) Company Information, Head Office, and Major Competitors
Table 62. 3SBio (Sunshine Guojian) Major Business
Table 63. 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Product and Solutions
Table 64. 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. 3SBio (Sunshine Guojian) Recent Developments and Future Plans
Table 66. Akeso Company Information, Head Office, and Major Competitors
Table 67. Akeso Major Business
Table 68. Akeso Severe Eosinophilic Asthma Treatment Product and Solutions
Table 69. Akeso Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Akeso Recent Developments and Future Plans
Table 71. InnoCare Pharma Company Information, Head Office, and Major Competitors
Table 72. InnoCare Pharma Major Business
Table 73. InnoCare Pharma Severe Eosinophilic Asthma Treatment Product and Solutions
Table 74. InnoCare Pharma Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. InnoCare Pharma Recent Developments and Future Plans
Table 76. Innovent Biologics Company Information, Head Office, and Major Competitors

Table 77. Innovent Biologics Major Business

Table 78. Innovent Biologics Severe Eosinophilic Asthma Treatment Product and Solutions

Table 79. Innovent Biologics Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 80. Innovent Biologics Recent Developments and Future Plans

Table 81. Mabwell Bioscience Company Information, Head Office, and Major Competitors

Table 82. Mabwell Bioscience Major Business

Table 83. Mabwell Bioscience Severe Eosinophilic Asthma Treatment Product and Solutions

Table 84. Mabwell Bioscience Severe Eosinophilic Asthma Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 85. Mabwell Bioscience Recent Developments and Future Plans

Table 86. Global Severe Eosinophilic Asthma Treatment Revenue (USD Million) by Players (2021-2026)

Table 87. Global Severe Eosinophilic Asthma Treatment Revenue Share by Players (2021-2026)

Table 88. Breakdown of Severe Eosinophilic Asthma Treatment by Company Type (Tier 1, Tier 2, and Tier 3)

Table 89. Market Position of Players in Severe Eosinophilic Asthma Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 90. Head Office of Key Severe Eosinophilic Asthma Treatment Players

Table 91. Severe Eosinophilic Asthma Treatment Market: Company Product Type Footprint

Table 92. Severe Eosinophilic Asthma Treatment Market: Company Product Application Footprint

Table 93. Severe Eosinophilic Asthma Treatment New Market Entrants and Barriers to Market Entry

Table 94. Severe Eosinophilic Asthma Treatment Mergers, Acquisition, Agreements, and Collaborations

Table 95. Global Severe Eosinophilic Asthma Treatment Consumption Value (USD Million) by Type (2021-2026)

Table 96. Global Severe Eosinophilic Asthma Treatment Consumption Value Share by Type (2021-2026)

Table 97. Global Severe Eosinophilic Asthma Treatment Consumption Value Forecast by Type (2027-2032)

Table 98. Global Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026)

Table 99. Global Severe Eosinophilic Asthma Treatment Consumption Value Forecast by Application (2027-2032)

Table 100. North America Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 101. North America Severe Eosinophilic Asthma Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 102. North America Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 103. North America Severe Eosinophilic Asthma Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 104. North America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 105. North America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 106. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 107. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 108. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 109. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 110. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 111. Europe Severe Eosinophilic Asthma Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 112. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 113. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 114. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 115. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 116. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026) & (USD Million)

Table 117. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value by Region (2027-2032) & (USD Million)

Table 118. South America Severe Eosinophilic Asthma Treatment Consumption Value

by Type (2021-2026) & (USD Million)

Table 119. South America Severe Eosinophilic Asthma Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 120. South America Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 121. South America Severe Eosinophilic Asthma Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 122. South America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 123. South America Severe Eosinophilic Asthma Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 124. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 125. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 126. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 127. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 128. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 129. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 130. Global Key Players of Severe Eosinophilic Asthma Treatment Upstream (Raw Materials)

Table 131. Global Severe Eosinophilic Asthma Treatment Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Severe Eosinophilic Asthma Treatment Picture
- Figure 2. Global Severe Eosinophilic Asthma Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type in 2025
- Figure 4. Intravenous Infusion
- Figure 5. Subcutaneous Injection
- Figure 6. Global Severe Eosinophilic Asthma Treatment Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
- Figure 7. Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Administration Route in 2025
- Figure 8. Inhalation Therapy
- Figure 9. Subcutaneous Injection Therapy
- Figure 10. Intravenous Infusion Therapy
- Figure 11. Global Severe Eosinophilic Asthma Treatment Consumption Value by Treatment Stage, (USD Million), 2021 & 2025 & 2032
- Figure 12. Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Treatment Stage in 2025
- Figure 13. Induction Remission Therapy
- Figure 14. Maintenance Control Therapy
- Figure 15. Exacerbation Rescue Therapy
- Figure 16. Global Severe Eosinophilic Asthma Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 17. Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application in 2025
- Figure 18. Adult Severe Eosinophilic Asthma Picture
- Figure 19. Adolescent Severe Eosinophilic Asthma Picture
- Figure 20. Elderly Comorbid Asthma Picture
- Figure 21. Global Severe Eosinophilic Asthma Treatment Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 22. Global Severe Eosinophilic Asthma Treatment Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 23. Global Market Severe Eosinophilic Asthma Treatment Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
- Figure 24. Global Severe Eosinophilic Asthma Treatment Consumption Value Market

Share by Region (2021-2032)

Figure 25. Global Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Region in 2025

Figure 26. North America Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 27. Europe Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 28. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 29. South America Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 30. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 31. Company Three Recent Developments and Future Plans

Figure 32. Global Severe Eosinophilic Asthma Treatment Revenue Share by Players in 2025

Figure 33. Severe Eosinophilic Asthma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 34. Market Share of Severe Eosinophilic Asthma Treatment by Player Revenue in 2025

Figure 35. Top 3 Severe Eosinophilic Asthma Treatment Players Market Share in 2025

Figure 36. Top 6 Severe Eosinophilic Asthma Treatment Players Market Share in 2025

Figure 37. Global Severe Eosinophilic Asthma Treatment Consumption Value Share by Type (2021-2026)

Figure 38. Global Severe Eosinophilic Asthma Treatment Market Share Forecast by Type (2027-2032)

Figure 39. Global Severe Eosinophilic Asthma Treatment Consumption Value Share by Application (2021-2026)

Figure 40. Global Severe Eosinophilic Asthma Treatment Market Share Forecast by Application (2027-2032)

Figure 41. North America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type (2021-2032)

Figure 42. North America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2032)

Figure 43. North America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Country (2021-2032)

Figure 44. United States Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 45. Canada Severe Eosinophilic Asthma Treatment Consumption Value

(2021-2032) & (USD Million)

Figure 46. Mexico Severe Eosinophilic Asthma Treatment Consumption Value

(2021-2032) & (USD Million)

Figure 47. Europe Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type (2021-2032)

Figure 48. Europe Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2032)

Figure 49. Europe Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Country (2021-2032)

Figure 50. Germany Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 51. France Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 52. United Kingdom Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 53. Russia Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 54. Italy Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 55. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type (2021-2032)

Figure 56. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2032)

Figure 57. Asia-Pacific Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Region (2021-2032)

Figure 58. China Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 59. Japan Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 60. South Korea Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 61. India Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 62. Southeast Asia Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 63. Australia Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 64. South America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type (2021-2032)

Figure 65. South America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2032)

Figure 66. South America Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Country (2021-2032)

Figure 67. Brazil Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 68. Argentina Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 69. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Type (2021-2032)

Figure 70. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Application (2021-2032)

Figure 71. Middle East & Africa Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Country (2021-2032)

Figure 72. Turkey Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 73. Saudi Arabia Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 74. UAE Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 75. Severe Eosinophilic Asthma Treatment Market Drivers

Figure 76. Severe Eosinophilic Asthma Treatment Market Restraints

Figure 77. Severe Eosinophilic Asthma Treatment Market Trends

Figure 78. Porters Five Forces Analysis

Figure 79. Severe Eosinophilic Asthma Treatment Industrial Chain

Figure 80. Methodology

Figure 81. Research Process and Data Source

I would like to order

Product name: Global Severe Eosinophilic Asthma Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GD83D051A02EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD83D051A02EEN.html>